Related Experiment Videos
A review on the putative association between beta-blockers and depression
Daniëlle E P Verbeek1, Jerry van Riezen, Rudolf A de Boer
1Department of Internal Medicine, Ziekenhuisgroep Twente, Almelo, The Netherlands. verbeek.dep@gmail.com
Heart Failure Clinics
|November 27, 2010
Summary
Beta-blockers generally do not cause depression, though vigilance is needed for susceptible individuals. Clinicians should not avoid prescribing beta-blockers due to depression fears.
Area of Science:
- Pharmacology
- Cardiology
- Psychiatry
Background:
- Systematic reviews have investigated the link between beta-blockers and depressive symptoms.
- Previous studies often exhibited significant design limitations.
- Most research indicates no general association between beta-blocker use and depression.
Purpose of the Study:
- To evaluate the association between beta-blocker use and depressive symptoms.
- To address limitations in prior study designs.
- To inform clinical practice regarding beta-blocker prescription.
Main Methods:
- Systematic review of existing studies.
- Analysis of study designs and reported outcomes.
- Consideration of individual patient factors and beta-blocker properties.
Main Results:
- The majority of studies found no evidence of beta-blockers causing depressive symptoms.
- Individual susceptibility to side effects cannot be entirely excluded.
- Lipophilic beta-blockers may warrant closer attention in specific patient groups.
Conclusions:
- Clinicians should remain aware of potential, though uncommon, links between beta-blockers and depression.
- Vigilance is recommended for patients with a history of depression or family history, especially when using lipophilic beta-blockers.
- Fear of inducing depression should not deter the appropriate prescription of beta-blockers for cardiovascular conditions.
Related Concept Videos
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:28Antihypertensive Drugs: Types of β-Blockers
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
01:17Antihypertensive Drugs: Action of β1 Blockers
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
01:18Depression: Overview
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...